Intrexon will ultimately get approval to combat the Zika virus in the United States, its chief executive predicted Friday.
The biotech company's subsidiary Oxitec has produced genetically modified mosquitoes that can be used to compete with normal Aedes aegypti mosquitoes that transmit the virus. Oxitec's mosquitoes can stop the spread of Zika by passing along a gene to their offspring that makes them die young.
CEO R.J. Kirk said he's spent the past several days in Washington pressing his case.
"I'm now very sanguine that we will have approval in the U.S. eventually because I see that the leadership in the U.S. is coalescing around the idea … that we really need to eliminate or at least vastly reduce the population of the Aedes aegypti mosquito and I think they are really starting to get our technology," Kirk said in an interview with CNBC's "Closing Bell."
"We're ready to go now. We're ready to deploy."